This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


New Indications for Antidepressants

Alan F. Schatzberg, MD

Published: September 30, 2000

Article Abstract

The second and third generation of antidepressants, i.e., the selective serotonin reuptake inhibitors, nefazodone,venlafaxine, and mirtazapine, are proving to be useful in a variety of seemingly diverse disorders, includingmost anxiety disorders. In addition to receiving approval from the U.S. Food and Drug Administration(FDA) for major depressive disorder, some of the newer antidepressants have received FDA approval for otherdisorders, e.g., generalized anxiety disorder (venlafaxine), bulimia nervosa (fluoxetine), obsessive-compulsivedisorder (fluvoxamine, paroxetine, sertraline, and fluoxetine), social phobia (paroxetine), panic disorder (sertraline,paroxetine), and posttraumatic stress disorder (sertraline). In controlled studies, these agents have alsoshown usefulness in premenstrual dysphoric disorder, borderline personality disorder, obesity, smoking cessation,and alcoholism. This article describes the new and potential indications for recently developed antidepressantsand the studies that suggested these indications.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: